# ExSure Pvt.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/exsure-pvt

- Industry: Biotechnology
- Headquarters: Odisha, India
- Website: www.exsure.in
- Total disclosed funding: $0.2M
- Latest round: Seed (Jan 11, 2025)
- Investors on record: 1

## About

Based in Odisha, India, and founded in 2021 by co-founders Swastika Paul and Abhishek Dutta, ExSure Pvt. Ltd. operates as a biotechnology research company that develops exosome-based cancer therapeutics and provides outsourcing services for cell-culture, exosome experimentation, and cancer stem cell assays. In January 2025, ExSure Pvt. Ltd. raised INR 30 million in seed funding led by Unicorn India Ventures.

ExSure Pvt. Ltd. specializes in cancer therapy through its exosome-based anti-cancer drug delivery platform, designed to target cancer stem cells responsible for relapses. The company’s offering includes a formulation that selectively targets these cancer stem cells while preserving healthy cells. This technology focuses on improving relapse-free survival rates for patients undergoing cancer treatment. The firm’s services include the isolation and characterization of cancer stem cells from various biological samples and the generation of a human cancer tissue-derived stem cell bank, serving healthcare providers and research institutions.

The company plans to use the funding from January 2025 to complete the non-clinical study of its exosome-based drug delivery platform, support its global expansion plans with in-house manufactured R&D products, and promote its offerings, including Exosure, Leucosure, PlantExosure, and Dr. Berries.

## Funding rounds

- Seed, Jan 11, 2025, $0.2M — Unicorn India Ventures

## Investors

- Unicorn India Ventures (https://capitalatlas.ai/funds/unicorn-india-ventures) — Seed